JP2025504278A5 - - Google Patents

Info

Publication number
JP2025504278A5
JP2025504278A5 JP2024530469A JP2024530469A JP2025504278A5 JP 2025504278 A5 JP2025504278 A5 JP 2025504278A5 JP 2024530469 A JP2024530469 A JP 2024530469A JP 2024530469 A JP2024530469 A JP 2024530469A JP 2025504278 A5 JP2025504278 A5 JP 2025504278A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
antibody
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/034872 external-priority patent/WO2024081274A1/en
Publication of JP2025504278A publication Critical patent/JP2025504278A/ja
Publication of JP2025504278A5 publication Critical patent/JP2025504278A5/ja
Pending legal-status Critical Current

Links

JP2024530469A 2022-10-12 2023-10-11 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法 Pending JP2025504278A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263415526P 2022-10-12 2022-10-12
US63/415,526 2022-10-12
US202263415928P 2022-10-13 2022-10-13
US63/415,928 2022-10-13
US202363449478P 2023-03-02 2023-03-02
US63/449,478 2023-03-02
PCT/US2023/034872 WO2024081274A1 (en) 2022-10-12 2023-10-11 Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (2)

Publication Number Publication Date
JP2025504278A JP2025504278A (ja) 2025-02-12
JP2025504278A5 true JP2025504278A5 (enExample) 2025-03-18

Family

ID=90670011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530469A Pending JP2025504278A (ja) 2022-10-12 2023-10-11 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法

Country Status (12)

Country Link
US (3) US20260144865A1 (enExample)
EP (1) EP4601693A1 (enExample)
JP (1) JP2025504278A (enExample)
KR (1) KR20250084959A (enExample)
CN (1) CN120265320A (enExample)
AU (1) AU2023361390A1 (enExample)
CL (2) CL2025001101A1 (enExample)
CO (1) CO2025004617A2 (enExample)
IL (1) IL320229A (enExample)
MX (1) MX2025004328A (enExample)
TW (3) TWI887800B (enExample)
WO (1) WO2024081274A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
EP4684798A3 (en) * 2025-09-12 2026-05-06 Qilu Pharmaceutical Co., Ltd. A high-concentration composition of pd-1 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3186281B1 (en) * 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
WO2021242728A1 (en) * 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
US20230365692A1 (en) * 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
CA3196535A1 (en) * 2020-10-28 2022-05-05 Alfredo C. Castro Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
PT4267105T (pt) * 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) * 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors

Similar Documents

Publication Publication Date Title
Ducreux et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
JP2025020147A5 (enExample)
Kouroussis et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
JP2022544280A5 (enExample)
JP2023546009A5 (enExample)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2020536887A5 (enExample)
JP2022527334A5 (enExample)
JP2024513247A5 (enExample)
JP2021527083A5 (enExample)
IL320229A (en) Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
Sun et al. Phase II study of S-1 plus cisplatin as first-line therapy in patients with metastatic esophageal carcinoma
Chen et al. Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non–small-cell lung cancer
CN115429883A (zh) 用于联合治疗的抗肿瘤药物组合物
CN115461079A (zh) 用于治疗肾癌的联用药物
JP2021529777A5 (enExample)
Fujitani et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer
JP2021530502A5 (enExample)
JP2021523096A5 (enExample)
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
Di Lauro et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
Zheng et al. Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: Updated results
Obarevich et al. Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)
TW201929900A (zh) Ｐｄ－１抗體和阿帕替尼聯合治療三陰性乳腺癌的用途
JP2024536201A5 (enExample)